TQ05105
Phase 1Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.TQ05105 is one of 117 small molecule programs targeting Histiocytosis. It is currently in Phase 1.
3
Indications
14
Total Trials
5
Active Trials
116
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
139 competitors in Myelofibrosis
#DrugCompanyPhaseTrials
1Ojjaara
GGlaxo Dba Glaxosmithkline
Phase 3
Vonjo
OOrsoBio, Inc
Phase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Rytelo
GGeron Corporation
Phase 3
Best Available Therapy
NovartisPhase 3
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Navitoclax
AbbViePhase 3
Fludara
SanofiPhase 2
Thalomid
Bristol-Myers SquibbPhase 2
Cytosar
TevaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Myelofibrosis4 trials
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT05020652·107 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT05020652·107 enrolledChronic Graft Versus Host Disease2 trials
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT04944043·45 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT04944043·45 enrolledMyeloproliferative Neoplasms1 trial
Histiocytosis1 trial
5 more indications
Acute Graft Versus Host Disease1 trial
Hepatic Impairment1 trial
Renal Impairment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TQ05105. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details